Non-Invasive Physiology and Pharmacology Using 19F Magnetic Resonance

Fluorine and Health

Volumn , Issue , 2008, Pages 197-276

  Yu, Jian Xin ^a   Cui, Weina ^a   Zhao, Dawen ^a   Mason, Ralph P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882833643     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53086-8.00005-9     Document Type: Chapter

References (435)

1. Zhang Z., Nair S.A., McMurry T.J. Gadolinium meets medicinal chemistry: MRI contrast agent development. Curr. Med. Chem. 2005, 12:751-778.
2. Baudelet C., Gallez B. Current issues in the utility of blood oxygen level dependent MRI for the assessment of modulations in tumor oxygenation. Curr. Med. Imag. Rev. 2005, 1:229-243.
3. Water Suppression 1992, 149-168. Oxford, Pergamon. D. Liebfritz, J.D. de Certaines, W.M.M.J. Bovee, F. Podo (Eds.).
4. O'Hagan D., Harper D.B. Fluorine-containing natural products. J. Fluorine Chem. 1999, 100:127-133.
5. Thomas S.R., Partain C.L. The Biomedical Applications of Fluorine-19 NMR 1988, Vol. 2:1536-1552. W.B. Saunders Co., London. R.R. Price, J.A. Patton, M.V. Kulkarni, A.E.J. James (Eds.).
6. 19F NMR 1992, Vol. 11:241-276. Plenum, New York. J. Reuben (Ed.).
7. 19F NMR Spectroscopy and Imaging In-Vivo 1992, 103-130. Springer-Verlag, Berlin.
8. London R.E., Gillies R.J. In Vivo NMR Studies Utilizing Fluorinated NMR Probes 1994, 263-277. Academic, San Diego.
9. 19F NMR of perfluorocarbon. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:1141-1153.
10. Zhao D., Jiang L., Mason R.P. Measuring changes in tumor oxygenation. Meth. Enzymol. 2004, 386:378-418.
11. Mason R.P. Transmembrane pH gradients in vivo: Measurements using fluorinated vitamin B6 derivatives. Curr. Med. Chem. 1999, 6:481-499.
12. McSheehy P.M.J., Lemaire L.P., Griffiths J.R., Grant D.M. Fluorine-19 MRS: Applications in Oncology 1996, 2048-2051. Wiley, Chichester. R.K. Harris (Ed.).
13. Menon D.K. Fluorine-19 MRS: General Overview and Anesthesia 1995, 2052-2063. Wiley, Chichester. R.K. Harris (Ed.).
14. Passe T.J., Charles H.C., Rajagopalan P., Krishnan K.R. Nuclear magnetic resonance spectroscopy: A review of neuropsychiatric applications, nuclear magnetic resonance spectroscopy: A review of neuropsychiatric applications. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19:541-563.
15. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Prog. Nucl. Magn. Reson. Spectrosc. 1998, 33:1-56.
16. Martino R., Malet-Martino M., Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug Metab. 2000, 1:271-303.
17. Wolf W., Presant C.A., Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 2000, 41:55-74.
18. 19F: A versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr. Med. Chem. 2005, 12:818-848.
19. Bohm H.J., Banner D., Bendels S., Kansy M., Kuhn B., Muller K., Obst-Sander U., Stahl M. Fluorine in medicinal chemistry. Chembiochem 2004, 5:637-643.
20. Ojima I. Use of fluorine in the medicinal chemistry and chemical biology of bioactive compounds-A case study on fluorinated taxane anticancer agents. Chembiochem 2004, 5:628-635.
21. Dolbier W.R. Fluorine chemistry at the millennium. J. Fluorine Chem. 2005, 126:157-163.
22. Park B.K., Kitteringham N.R., O'Neill P.M. Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41:443-470.
23. Jackel C., Koksch B. Fluorine in peptide design and protein engineering. Eur. J. Org. Chem. 2005, (21):4483-4503.
24. Shimizu M., Hiyama T. Modern synthetic methods for fluorine-substituted target molecules. Angew. Chem. Int. Ed. 2005, 44:214-231.
25. Plenio H. The coordination chemistry of fluorine in fluorocarbons. Chembiochem 2004, 5:650-655.
26. Jeschke P. The unique role of fluorine in the design of active ingredients for modern crop protection. Chembiochem 2004, 5:570-589.
27. Ismail F.M.D. Important fluorinated drugs in experimental and clinical use. J. Fluorine Chem. 2002, 118:27-33.
28. Isanbor C., O'Hagan D. Fluorine in medicinal chemistry: A review of anti-cancer agents. J. Fluorine Chem. 2006, 127:303-319.
29. Oyiliagu C.E., Novalen M., Kotra L.P. Fluorine containing molecules for peptidomimicry: A chemical act to modulate enzymatic activity. Mini-Rev. Organic Chem. 2006, 3:99-115.
30. Zanda M. Trifluoromethyl group: An effective xenobiotic function for peptide backbone modification. New J. Chem. 2004, 28:1401-1411.
31. Vol. http://www.nibib.nih.gov/in.
32. in Vol. http://imaging.cancer.gov/.
33. http://www.molecularimaging.org.
34. http://www.ismrm.org/.
35. in Vol. http://interactive.snm.org/.
36. Mason R.P., Ran S., Thorpe P.E. Quantitative assessment of tumor oxygen dynamics: Molecular Imaging for Prognostic Radiology. J. Cell. Biochem. 2002, 87(Suppl.):45-53.
37. Karam J.A., Mason R.P., Koeneman K.S., Antich P.P., Benaim E.A., Hsieh J.T. Molecular imaging in prostate cancer. J. Cell. Biochem. 2003, 90:473-483.
38. Contag C.H., Ross B.D. It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology. J. Magn. Reson. Imaging 2002, 16:378-387.
39. Kumar R., Jana S. Positron emission tomography: An advanced nuclear medicine imaging technique from research to clinical practice. Methods Enzymol. 2004, 385:3-19.
40. in Vol. http://probes.invitrogen.com/handbook/.
41. in Vol. http://www.cri-inc.com/products/maestro.asp.
42. Oldham M., Sakhalkar H., Oliver T., Wang Y.M., Kirpatrick J., Cao Y.T., Badea C., Johnson G.A., Dewhirst M. Three-dimensional imaging of xenograft tumors using optical computed and emission tomography. Med. Phys. 2006, 33:3193-3202.
43. Zacharakis G., Kambara H., Shih H., Ripoll J., Grimm J., Saeki Y., Weissleder R., Ntziachristos V. Volumetric tomography of fluorescent proteins through small animals in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:18252-18257.
44. Derfus A.M., Chan W.C.W., Bhatia S.N. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004, 4:11-18.
45. Hoffman R. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol. 2002, 3:546-556.
46. Contag C.H., Spilman S.D., Contag P.R., Oshiro M., Eames B., Dennery P., Stevenson D.K., Benaron D.A. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Photobiol. 1997, 66:523-531.
47. Richer E., Slavine N., Lewis M.A., Tsyganov E., Gellert G.C., Gunnur Dikmen Z., Bhagwandin V., Shay J.W., Mason R.P., Antich P.P. Society of Molecular Imaging (St. Louis) 2004.
48. Blankenberg F., Eckelman W.C., Strauss H.W., Welch M.J., Alavi A., Anderson C., Bacharach S., Blasberg R.G., Graham M.M., Weber W. Role of radionuclide imaging in trials of antiangiogenic therapy. [Review]. Acad. Radiol. 2000, 7:851-867.
49. Haberkorn U., Mier W., Eisenhut M. Scintigraphic imaging of gene expression and gene transfer. Curr. Med. Chem. 2005, 12:779-794.
50. Vranjesevic D., Filmont J.E., Meta J., Silverman D.H., Phelps M.E., Rao J., Valk P.E., Czernin J. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J. Nucl. Med. 2002, 43:325-329.
51. Seo Y., Franc B.L., Hawkins R.A., Wong K.H., Hasegawa B.H. Progress in SPECT/CT imaging of prostate cancer. Technol. Cancer Res. Treat. 2006, 5:329-336.
52. Love C., Din A.S., Tomas M.B., Kalapparambath T.P., Palestro C. Radionuclide bone imaging: An illustrative review. Radiographics 2003, 23:341-358.
53. Cherin E., Williams R., Needles A., Liu G.W., White C., Brown A.S., Zhou Y.Q., Foster F.S. Ultrahigh frame rate retrospective ultrasound microimaging and blood flow visualization in mice in vivo. Ultrasound Med. Biol. 2006, 32:683-691.
54. Tepel M., Aspelin P., Lameire N. Contrast-induced nephropathy: A clinical and evidence-based approach. Circulation 2006, 113:1799-1806.
55. Mishima H., Kobayashi T., Shimizu M., Tamaki Y., Baba M. In vivo F-19 chemical shift imaging with FTPA and antibody-coupled FMIQ. J. Magn. Reson. Imaging 1991, 1:705-709.
56. Morawski A.M., Winter P.M., Yu X., Fuhrhop R., Scott M.J., Hockett F., Robertson J.D., Gaffney P.J., Lanza G.M., Wickline S.A. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 2004, 52:1255-1262.
57. Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., Saido T.C. F-19 and H-1 MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 2005, 8:527-533.
58. Harris R.K., Becker E.D., Cabral de Menezes S.M., Goodfellow R., Granger P. NMR nomenclature. Nuclear spin properties and conventions for chemical shifts (IUPAC Recommendations 2001). Pure Appl. Chem. 2001, 73:1795-1818.
59. Bovey F.A. Nuclear Magnetic Resonance Spectroscopy 1988, 653. Academic Press, San Diego.
60. Emsley J.W., Phillips L. Fluorine chemical shifts. Prog. Nucl. Magn. Reson. Spectrosc. 1971, 7:1-520.
61. Emsley J.W., Phillips L., Wray V. Fluorine coupling constants. Prog. Nucl. Magn. Reson. Spectrosc. 1976, 10:83-756.
62. Shukla H.P., Mason R.P., Woessner D.E., Antich P.P. A comparison of three commercial perfluorocarbon emulsions as high field NMR probes of oxygen tension and temperature. J. Magn. Reson. Series B. 1995, 106:131-141.
63. van Laarhoven H.W.M., Punt C.J.A., Kamm Y.J.L., Heerschap A. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo 19F magnetic resonance spectroscopy. Crit. Rev. Oncol./Hematol. 2005, 56:321-343.
64. 19F nuclear magnetic resonance spectrometry. Cancer Res. 1986, 46:2105-2112.
65. Blackstock A.W., Lightfoot H., Case L.D., Tepper J.E., Mukherji S.K., Mitchell B.S., Swarts S.G., Hess S.M. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: Correlation with in vivo tumor response. Clin. Cancer Res. 2001, 7:3263-3268.
66. Payne G.S., Collins D.J., Loynds P., Mould G., Murphy P.S., Dzik-Jurasz A.S.K., Kessar P., Haque N., Yamaguchi M., Atarashi S., Leach M.O. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo F-19 magnetic resonance spectroscopy. Br. J. Clin. Pharmacol. 2005, 59:244-248.
67. Bilecen D., Schulte A.C., Kaspar A., Kustermann E., Seelig J., von Elverfeldt D., Scheffler K. Detection of the non-steroidal anti-inflammatory drug niflumic acid in humans: A combined F-19-MRS in vivo and in vitro study. NMR Biomed. 2003, 16:144-151.
68. Schneider E., Bolo N.R., Frederick B., Wilkinson S., Hirashima F., Nassar L., Lyoo I.K., Koch P., Jones S., Hwang J., Sung Y., Villafuerte R.A., Maier G., Hsu R., Hashoian R., Renshaw P.F. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: Validation using an investigation of liver and heart disposition of tecastemizole. J. Clin. Pharm. Ther. 2006, 31:261-273.
69. 19F nuclear magnetic resonance. Magn. Reson. Med. 2002, 48:255-261.
70. Henry M.E., Schmidt M.E., Hennen J., Villafuerte R.A., Butman M.L., Tran P., Kerner L.T., Cohen B., Renshaw P.F. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology 2005, 30:1576-1583.
71. Strauss W.L., Unis A.S., Cowan C., Dawson G., Dager S.R. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am. J. Psychiatry 2002, 159:755-760.
72. 19F magnetic resonance spectroscopy. Brain Res. 1999, 834:1-5.
73. Chung Y.L., Troy H., Judson I.R., Leek R., Leach M.O., Stubbs M., Harris A.L., Griffiths J.R. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. Clin. Cancer Res. 2004, 10:3863-3870.
74. 19F NMR Measurements of Intracellular pH 1987, 55-73. CRC Press, Boca Raton.
75. Smart B.E. Fluorine substituent effects (on bioactivity). J. Fluorine Chem. 2001, 109:3-11.
76. Gerebtzoff G., Li-Blatter X., Fischer H., Frentzel A., Seelig A. Halogenation of drugs enhances membrane binding and permeation. Chembiochem 2004, 5:676-684.
77. Shainyan B.A., Danilevich Y.S., Grigor'eva A.A., Chuvashev Y.A. Electrochemical fluorination of benzamide and acetanilide in anhydrous HF and in acetonitrile. Russian J. Org. Chem. (Trans. Zh. Organ. Khim.). 2004, 40:513-517.
78. Olah G.A., Nojima M., Kerekes I. Synthetic methods and reactions. I. Seleniuum tetrafluoride and its pyridine complex. Convenient fluorinating agents for fluorination of ketones, aldehydes, amides, alcohols, carboxylic acids, and anhydrides. J. Am. Chem. Soc. 1974, 96:925-927.
79. Haas A., Maciej T. Fluorination by tungsten hexafluoride. J. Fluorine Chem. 1982, 20:581-587.
80. Patrick T.B., Zhang L., Li Q. Rearrangement and double fluorination in the deiodinative fluorination of neopentyl iodide with xenon difluoride. J. Fluorine Chem. 2000, 102:11-15.
81. Belen'kii G.G., Petrov V.A., Resnick P.R. Electrophilic, catalytic alkylation of polyfluoroolefins by some fluoroalkanes. J. Fluorine Chem. 2001, 108:15-20.
82. Adachi K., Ohira Y., Tomizawa G., Ishihara S., Oishi S. Electrophilic fluorination with N,N′-difluoro-2,2′-bipyridinium salt and elemental fluorine. J. Fluorine Chem. 2003, 120:173-183.
83. 19F magnetic resonance imaging: Synthesis & characterization of fluorinated polymers. Bioorg. Med. Chem. Lett. 1992, 2:527-532.
84. Joubert J., Roussel S., Christophe C., Billard T., Langlois B.R., Vidal T. Trifluoroacetamides from amino alcohols as nucleophilic trifluoromethylating reagents. Angew. Chem. Int. Ed. 2003, 42:3133-3136.
85. Rasey J.S., Casciari J.J., Hofstrand P.D., Muzi M., Graham M.M., Chin L.K. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat. Res. 2000, 153:84-92.
86. Dolbier W.R., Li A.R., Koch C.J., Shiue C.Y., Kachur A.V. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl. Radiat. Isot. 2001, 54:73-80.
87. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006, 129:393-401.
88. Zanzonico P., Campa J., Polycarpe-Holman D., Forster G., Finn R., Larson S., Humm J., Ling C. Animal-specific positioning molds for registration of repeat imaging studies: Comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl. Med. Biol. 2006, 33:65-70.
89. Spratt N.J., Ackerman U., Tochon-Danguy H.J., Donnan G.A., Howells D.W. Characterization of fluoromisonidazole binding in stroke. Stroke 2006, 37:1862-1867.
90. Bussink J., Troost E.G.C., Laverman P., Philippens M., Lok J., Boerman O.C., Kaanders J., van der Kogel A.J. Characterization of human squamous cell head and neck carcinoma xenografts using 18F-FLT and 18F-MISO autoradiography and immunohistochemistry. Radiother. Oncol. 2006, 78:S33.
91. Keupp J., Mazurkewitz P.C., Gräßlin I., Schaeffter T. Proc. Intl. Soc. Mag. Reson. Med. 2006, 102.
92. 19F spectroscopy and relaxometry of perfluorocarbon emulsions in tissue. Magn. Reson. Med. 1990, 13:478-489.
93. Sanders J., Hunter B. Modern NMR Spectroscopy 1987, 308. Oxford University Press, New York.
94. Mason R.P., Cha G., Gorrie G.H., Babcock E.E., Antich P.P. Glutathione in whole blood: A novel determination using double quantum coherence transfer proton NMR spectroscopy. FEBS Lett. 1993, 318:30-34.
95. Hurd R.E., Freeman D.M. Metabolite specific proton magnetic-resonance imaging. Proc. Natl. Acad. Sci. USA 1989, 86:4402-4406.
96. Mason R.P., Sanders J.K.M. In vivo enzymology: A deuterium NMR study of formaldehyde dismutase in Pseudomonas putida F61a and Staphylococcus aureus. Biochemistry 1989, 28:2160-2168.
97. 13C NMR spectroscopy of S-(hydroxymethyl) glutathione as a transient intracellular intermediate. Biochemistry 1986, 25:4504-4507.
98. 19F spin relaxation in index finger bones. Mag. Reson. Med. 1990, 13:358-369.
99. Klomp D.W.J., van Laarhoven H.W.M., Kentgens A.P.M., Heerschap A. Optimization of localized F-19 magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. Magn. Reson. Med. 2003, 50:303-308.
100. 19F relaxation rate enhancement and frequency shift with Gd-DTPA. Invest. Radiol. 1989, 24:224-227.
101. 19F MR Characterization of Fluorinated Proteins and Relaxation Rate Enhancement with Gd-DTPA for Faster Imaging 1995, 305-313. Plenum, New York. E.H. Emram (Ed.).
102. Lee H., Price R.R., Holburn G.E., Partain C.L., Adams M.D., Cacheris W.P. In-Vivo F-19 MR-Imaging-Relaxation Enhancement with Gd-DTPA. J. Magn. Reson. Imaging 1994, 4:609-613.
103. Brix G., Bellemann M.E., Gerlach L., Haberkorn U. Intra- and extracellular fluorouracil uptake: Assessment with contrast-enhanced metabolic F-19 MR imaging. Radiology 1998, 209:259-267.
104. Li B.S.Y., Payne G.S., Collins D.J., Leach M.O. H-1 decoupling for in vivo F-19 MRS studies using the time-share modulation method on a clinical 1.5 T NMR system. Magn. Reson. Med. 2000, 44:5-9.
105. Kendrick R.D., Yannoni C.S. High-Power H-1-F-19 Excitation in a Multiple-Resonance Single-Coil Circuit. J. Magn. Reson. 1987, 75:506-508.
106. Lantum H.B., Baggs R.B., Krenitsky D.M., Anders M.W. Nephrotoxicity of chlorofluoroacetic acid in rats. Toxicol. Sci. 2002, 70:261-268.
107. Hassel B., Sonnewald U., Unsgard G., Fonnum F. NMR-spectroscopy of cultured astrocytes-Effects of glutamine and the gliotoxin fluorocitrate. J. Neurochem. 1994, 62:2187-2194.
108. Frost R.L., Parker R.W., Hanna J.V. Detection of the pesticide compound-1080 (sodium monofluoroacetate) using F-19 nuclear magnetic-resonance spectroscopy. Analyst 1989, 114:1245-1248.
109. Corcoran O., Lindon J.C., Hall R., Ismail I.M., Nicholson J.K. The potential of F-19 NMR spectroscopy for rapid screening of cell cultures for models of mammalian drug metabolism. Analyst 2001, 126:2103-2106.
110. Spraul M., Hofmann M., Wilson I.D., Lenz E., Nicholson J.K., Lindon J.C. Coupling of Hplc with F-19-NMR and H-1-NMR spectroscopy to investigate the human urinary-excretion of flurbiprofen metabolites. J. Pharm. Biomed. Anal. 1993, 11:1009-1015.
111. Bollard M.E., Holmes E., Blackledge C.A., Lindon J.C., Wilson I.D., Nicholson J.K. H-1 and F-19-nmr spectroscopic studies on the metabolism and urinary excretion of mono- and disubstituted phenols in the rat. Xenobiotica 1996, 26:255-273.
112. Preiss A., Kruppa J., Buschmann J., Mugge C. The determination of trifluoroacetic acid in rat milk samples by F-19-NMR spectroscopy and capillary gas chromatography. J. Pharm. Biomed. Anal. 1998, 16:1381-1385.
113. 19F HPLC-NMR spectroscopy. J. Pharm. Biomed. Anal. 2003, 30:1561-1574.
114. Duckett C.J., Lindon J.C., Walker H., Abou-Shakra F., Wilson I.D., Nicholson J.K. Metabolism of 3-chloro-4-fluoroaniline in rat using [C-14]-radiolabelling, F-19-NMR spectroscopy, HPLC-MS/MS, HPLC-ICPMS and HPLC-NMR. Xenobiotica 2006, 36:59-77.
115. Blackledge C.A., Nicholson J.K., Evans J.A., Rodgers C., Wilson I.D. Application of H-1- and F-19-NMR spectroscopy in the investigation of the urinary and biliary excretion of 3,5-, 2,4-ditrifluoromethylbenzoic and pentafluorobenzoic acids in rat. Xenobiotica 2002, 32:605-613.
116. Dubois B.W., Evers A.S. 19F-NMR spin-spin relaxation (T2) method for characterizing volatile anesthetic binding to proteins. Analysis of isoflurane binding to serum albumin. Biochemistry. 1992, 31:7069-7076.
117. Chew W.M., Moseley M.E., Mills P.A., Sessler D., Gonzalez-Mendez R., James T.L., Litt L. Spin-echo fluorine magnetic resonance imaging at 2 T: In vivo spatial distribution of halothane in the rabbit head. Magn. Reson. Imaging 1987, 5:51-56.
118. Menon D.K., Lockwood G.G., Peden C.J., Cox I.J., Sargentoni J., Bell J.D., Coutts G.A., Whitwam J.G. In-vivo F-19 magnetic-resonance spectroscopy of cerebral halothane in postoperative-patients-preliminary-results. Magn. Reson. Med. 1993, 30:680-684.
119. Babcock E.E., Vaughan J.T., Lesan B., Nunnally R.L. Multinuclear NMR investigations of probe construction materials at 4.7-T. Magn. Reson. Med. 1990, 13:498-503.
120. Morinelli T.A., Okwu A.K., Mais D.E., Halushka P.V., John V., Chen C.K., Fried J. Difluorothromboxane-A2 and stereoisomers-stable derivatives of thromboxane-A2 with differential-effects on platelets and blood-vessels. Proc. Natl.Acad. Sci. USA 1989, 86:5600-5604.
121. Dwek R.A. The Use of Fluorine-19 as a Detecting Shift Probe 1975, 158-173. Clarendon, Oxford. R.A. Dwek (Ed.).
122. Gerig J.T. Fluorine magnetic resonance of fluorinated ligands. Meth. Enzymol. 1989, 177:3-23.
123. Huestis W.H., Raftery M.A. Study of cooperative interactions in hemoglobin using fluorine nuclear magnetic resonance. Biochemistry 1972, 11:1648-1654.
124. Millett F., Raftery M.A. Fluorine-19 nuclear magnetic resonance study of the binding of trifluoroacetylglucosamine oligomers to lysozyme. Biochemistry 1972, 11:1639-1643.
125. Withers S.G., Rupitz K., Street I.P. 2-Deoxy-2-fluoro-D-glycosyl fluorides-a new class of specific mechanism-based glycosidase inhibitors. J. Biol. Chem. 1988, 263:7929-7932.
126. Withers S.G., Street I.P., Percival M.D. Fluorinated carbohydrates as probes of enzyme specificity and mechanism. ACS Symposium Series 1988, 374:59-77.
127. Stirtan W.G., Withers S.G. Phosphonate and alpha-fluorophosphonate analogue probes of the ionization state of pyridoxal 5′-phosphate (PLP) in glycogen phosphorylase. Biochemistry 1996, 35:15057-15064.
128. Szczecinski P., Bartusik D. F-19 NMR measurements-A potential tool for the determination of amino acids in body fluids. Pol. J. Chem. 2003, 77:321-328.
129. Sylvia L.A., Gerig J.T. Fluorine NMR-studies of the metabolism of flumecinol (3-trifluoromethyl-alpha-ethylbenzhydrol). Drug Metab. Dispos. 1993, 21:105-113.
130. Sidelmann U., Hansen S.H., Gavaghan C., Nicholls A.W., Carless H.A.J., Lindon J.C., Wilson I.D., Nicholson J.K. Development of a simple liquid chromatographic method for the separation of mixtures of positional isomers and anomers of synthetic 2-, 3- and 4-fluorobenzoic acid glucuronides formed via acyl migration reactions. J. Chromatogr. B: Biomed. Sci. Appl. 1996, 685:113-122.
131. Scarfe G.B., Tugnait M., Wilson I.D., Nicholson J.K. Studies on the metabolism of 4-fluoroaniline and 4-fluoroacetanilide in rat: Formation of 4-acetamidophenol (paracetamol) and its metabolites via defluorination and N-acetylation. Xenobiotica 1999, 29:205-216.
132. Ellis M.K., Naylor J.L., Green T., Collins M.A. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2-trifluoroethane (Hcfc133a) in the rat by F-19-Nmr spectroscopy. Drug Metab. Dispos. 1995, 23:102-106.
133. Heidelberger C. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nat. Chem. Biol. 1957, 179:663-666.
134. Presant C.A., Wolf W., Waluch V., Wiseman C., Kennedy P., Blayney D., Brechner R.R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 1994, 343:1184-1187.
135. Peters G.F.J. Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 1988, 6:1653-1664.
136. 19F MRI: A comparative animal study. Nucl. Med. Biol. 1996, 23:897-906.
137. Brix G., Bellemann M.E., Gerlach L., Haberkorn U. Direct detection of intratumoral 5-fluorouracil trapping using metabolic F-19 MR imaging. Magn. Reson. Imaging 1999, 17:151-155.
138. Brix G., Bellemann M.E., Haberkorn U., Gerlach L., Bachert P., Lorenz W.J. Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective F-19 MR-imaging. Magn. Reson. Med. 1995, 34:302-307.
139. 19F NMR spectroscopy. Cancer Res. 1991, 51:5770-5773.
140. Ojugo A.S.E., McSheehy P.M.J., Stubbs M., Alder G., Bashford C.L., Maxwell R.J., Leach M.O., Judson I.R., Griffiths J.R. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J. Cancer 1998, 77:873-879.
141. McSheehy P.M.J., Robinson S.P., Ojugo A.S.E., Aboagye E.O., Cannell M.B., Leach M.O., Judson I.R., Griffiths J.R. Carbogen breathing increases 5-Fluorouracil uptake and cytotoxicity in hypoxic Rif-1 tumors: A magnetic resonance study in vivo. Cancer Res. 1998, 58:1185-1194.
142. Griffiths J.R., McIntyre D.J.O., Howe F.A., McSheehy P.M.J., Ojugo A.S.E., Rodrigues L.M., Wadsworth P., Price N.M., Lofts F., Nicholson G., Smid K., Noordhuis P., Peters G.J., Stubbs M. Issues of normal tissue toxicity in patient and animal studies-Effect of carbogen breathing in rats after 5-fluorouracil treatment. Acta Oncol. 2001, 40:609-614.
143. van Laarhoven H., Gambarota G., Lok J., Lammens M., Kamm Y., Wagener T., Punt C., van der Kogel A., Heerschap A. Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with distinct vascular structures. Proc. Intl. Soc. Mag. Reson. Med. (Seattle) 2006, 1766.
144. Sijens P.E., Baldwin N.J., Ng T.C. Multinuclear MR investigation of the metabolic response of murine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn. Reson. Med. 1991, 19:337-385.
145. Lutz N.W., Hull W.E. Assignment and pH dependence of the 19F-NMR resonances from the fluorouracil anabolites involved in fluoropyrimidine chemotherapy. NMR Biomed. 1999, 12:237-248.
146. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., Aguilar-Cordova E., Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62:4968-4976.
147. Stegman L.D., Rehemtulla A., Beattie B., Kievit E., Lawrence T.S., Blasberg R.G., Tjuvajev J.G., Ross B.D. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. USA 1999, 96:9821-9826.
148. Stegman L.D., Rehemtulla A., Hamstra D.A., Rice D.J., Jonas S.J., Stout K.L., Chenevert T.L., Ross B.D. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther. 2000, 7:1005-1010.
149. Aghi M., Kramm C.M., Chou T.C., Breakefield X.O., Chiocca E.A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst. 1998, 90:370-380.
150. 19F-NMR spectroscopy. Gene Ther. 2002, 9:1564-1575.
151. Dresselaers T., Theys J., Dubois L., Landuyt W., Van Hecke P., Lambin P. Evaluation of salmonella-based suicide gene transfer in a rodent tumor model using in vivo 19F MR spectroscopy. Proc. Intl. Soc. Mag. Reson. Med. 2006, 3175.
152. Cron G.O., Beghein N., Ansiaux R., Gallez B. Botulinum toxin increases tumor uptake of gemcitabine chemotherapy as measured with fluorine spectroscopy. Proc. Intl. Soc. Mag. Reson. Med. (Seattle) 2006, 1764.
153. Bellemann M.E., Haberkorn U., Gerlach L., Blatter J., Brix G. Fluorine-19 NMR imaging of the biodistribution and metabolization of the antienoplastic agent gemcitabine in tumor-bearing rats 1999, 1352.
154. McSheehy P.M.J., Ojugo A.S.E., Leach M.O., Judson I.R., Griffiths J.R. 19F-MRS studies of the novel Theymidylate Synthase (TS) Inhibitor, ZD9331 1999, 1347.
155. Brix G., Schlicker A., Mier W., Peschke P., Bellemann M.E. Biodistribution and pharmacokinetics of the F-19-labeled radiosensitizer 3-aminobenzamide: Assessment by F-19 MR imaging. Magn. Reson. Imaging 2005, 23:967-976.
156. Spees W.M., Gade T.P.F., Yang G.L., Tong W.P., Bornmann W.G., Gorlick R., Koutcher J.A. An F-19 magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: Proof of principle. Clin. Cancer Res. 2005, 11:1454-1461.
157. Tengel T., Fex T., Emtenas H., Almqvist F., Sethson I., Kihlberg J. Use of F-19 NMR spectroscopy to screen chemical libraries for ligands that bind to proteins. Org. Biomol. Chem. 2004, 2:725-731.
158. Tarrago T., Frutos S., Rodriguez-Mias R.A., Giralt E. Identification by F-19 NMR of traditional chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity. Chembiochem 2006, 7:827-833.
159. Frutos S., Tarrago T., Giralt E. A fast and robust F-19 NMR-based method for finding new HIV-1 protease inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:2677-2681.
160. Yu L.P., Hajduk P.J., Mack J., Olejniczak E.T. Structural studies of Bcl-xL/ligand complexes using F-19 NMR. J. Biomol. NMR 2006, 34:221-227.
161. Bartels M., Albert K. Detection of psychoactive drugs using 19F MR spectroscopy. J. Neural Transm. Gen Sect. 1995, 99:1-6.
162. Bolo N.R., Hode Y., Macher J.P. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: A fluorine magnetic resonance spectroscopy study in vivo. MAGMA 2004, 16:268-276.
163. 19F magnetic resonance spectroscopy. Am. J. Psychiatry 1998, 155:380-384.
164. Lindquist D.M., Dachtler M., Hawk R.M., Karson C.N., Albert K., Komoroski R.A. Contribution of trifluoperazine metabolites to the in vivo F-19 NMR spectrum of rat brain. Magn. Reson. Med. 2000, 43:756-759.
165. Sassa T., Suhara T., Ikehira H., Obata T., Girard F., Tanada S., Okubo Y. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. Psychiatry Clin. Neurosci. 2002, 56:637-642.
166. Jynge P., Skjetne T., Gribbestad I., Kleinbloesem C.H., Hoogkamer H.F.W., Antonsen O., Krane J., Bakoy O.E., Furuheim K.M., Nilsen O.G. In vivo tissue pharmacokinetics by fluorine magnetic-resonance spectroscopy-a study of liver and muscle disposition of fleroxacin in humans. Clin. Pharmacol. Ther. 1990, 48:481-489.
167. Saether O., Midelfart A., Risa O., Haraldseth O., Krane J. Proton decoupled F-19 NMR spectroscopy of drugs used in eye treatment. Spectrosc. Lett. 2006, 39:135-144.
168. Gewiese B., Noske W., Schilling A., Stiller D., Wolf K., Foerster M. Human eye: Visualization of perfluorodecalin with F-19 MR imaging. Radiology 1992, 185:131-133.
169. 2 in the vitrectomized human eye using 19F NMR. Arch. Ophthalmol. 1992, 110:1098-1100.
170. Mason R.P., Babcock E.E., Nunnally R.L. 1988.
171. Nunnally R., Antich P., Nguyen P., Babcock E., McDonald G., Mason R. Fluosol adjuvant therapy in human cancer: Examinations in vivo of perfluorocarbons by F-19 NM 1988, 342.
172. 19F NMR imaging of halothane in rabbit brain 1988, 597.
173. Takeda T., Makita K., Ishikawa S., Kaneda K., Yokoyama K., Amaha K. Uptake and elimination of sevoflurane in rabbit tissues - an in vivo magnetic resonance spectroscopy study. Can. J. Anaesth. 2000, 47:579-584.
174. Xu Y., Tang P., Zhang W.G., Firestone L., Winter P.M. F-19 nuclear-magnetic-resonance imaging and spectroscopy of sevoflurane uptake, distribution, and elimination in rat-brain. Anesthesiology 1995, 83:766-774.
175. 19F one-dimensional chemical shift imaging study of isoflurane uptake in rabbit brain. NMR Biomed. 1993, 6:377-382.
176. Lockwood G.G., Dob D.P., Bryant D.J., Wilson J.A., Sargentoni J., Sapsed-Byrne S.M., Harris D.N.F., Menon D.K. Magnetic resonance spectroscopy of isoflurane kinetics in humans. 1. Elimination from the head. Br. J. Anaesth. 1997, 79:581-585.
177. Selinsky B.S., Perlman M.E., London R.E. In vivo nuclear magnetic resonance studies of hepatic methoxyflurane metabolism. I. Verification and quantitation of methoxydifluoroacetate. Mol. Pharmacol. 1988, 33:559-566.
178. Selinsky B.S., Perlman M.E., London R.E. In vivo nuclear magnetic-resonance studies of hepatic methoxyflurane metabolism. 2. A reevaluation of hepatic metabolic pathways. Mol. Pharmacol. 1988, 33:567-573.
179. Mazzola E.P., Borsetti A.P., Page S.W., Bristol D.W. Determination of pesticide-residues in foods by F-19 fourier-transform nuclear magnetic-resonance spectroscopy. J. Agric. Food Chem. 1984, 32:1102-1103.
180. Mortimer R.D., Dawson B.A. Using F-19 Nmr for trace analysis of fluorinated pesticides in food-products. J. Agric. Food. Chem. 1991, 39:1781-1785.
181. Zuo Z., Kwon G., Stevenson B., Diakur J., Wiebe L.I. Flutamide-Hydroxypropyl-beta-cyclodextrin complex: Formulation, physical characterization, and absorption studies using the Caco-2 in vitro model. J. Pharm. Pharm. Sci. 2000, 3:220-227.
182. Masson M., Sigurjonsdottir J.F., Jonsdottir S., Loftsson T. Examination of F-19-NMR as a tool for investigation of drug-cyclodextrin complexes. Drug Dev. Ind. Pharm. 2003, 29:107-112.
183. Fukuchi J., Kokontis J.M., Hiipakka R.A., Chuu C.P., Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 2004, 64:7686-7689.
184. Rofstad E.K., Danielsen T. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Br. J. Cancer 1999, 80:1697-1707.
185. Höckel M., Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
186. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 2003, 13:159-167.
187. Knowles H.J., Harris A.L. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. [Review]. Breast Cancer Res. 2001, 3:318-322.
188. Gray L., Conger A., Ebert M., Hornsey S., Scott O. The concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26:638-648.
189. Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S., Chapman J.D., Eckelman W.C., Fyles A.W., Giaccia A.J., Hill R.P., Koch C.J., Krishna M.C., Krohn K.A., Lewis J.S., Mason R.P., Melillo G., Padhani A.R., Powis G., Rajendran J.G., Reba R., Robinson S.P., Semenza G.L., Swartz H.M., Vaupel P., Yang D., Croft B., Hoffman J., Liu G., Stone H., Sullivan D. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 2006, 82:699-757.
190. Brown J.M. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol. Med. Today 2000, 6:157-162.
191. Swartz H.M., Dunn J.F., Dunn J.F. Measurements of Oxygen in Tissues: Overview and Perspectives on Methods 2003, Vol. 530:1-12. Kluwer Academic, New York. H.M. Swartz (Ed.).
192. Stone H.B., Brown J.M., Phillips T., Sutherland R.M. Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Radiat. Res. 1993, 136:422-434.
193. Liu H., Gu Y., Kim J.G., Mason R.P. Near infrared spectroscopy and imaging of tumor vascular oxygenation. Methods Enzymol. 2004, 386:349-378.
194. Mason R.P. Non-Invasive assessment of kidney oxygenation: A role for BOLD MRI. Kidney Int. 2006, 70:10-11.
195. Yee S.H., Lee K., Jerabek P.A., Fox P.T. Quantitative measurement of oxygen metabolic rate in the rat brain using microPET imaging of briefly inhaled 15O-labelled oxygen gas. Nucl. Med. Commun. 2006, 27:573-581.
196. Coles J.P., Fryer T.D., Bradley P.G., Nortje J., Smielewski P., Rice K., Clark J.C., Pickard J.D., Menon D.K. Intersubject variability and reproducibility of 15O PET studies. J. Cereb. Blood Flow Metab. 2006, 26:48-57.
197. Koch C.J. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol. 2002, 352:3-31.
198. Raleigh J.A., Chou S.C., Arteel G.E., Horsman M. Comparison among pimonidazole binding oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat. Res. 1999, 151:580-589.
199. 2 and radiosensitivity of tumors by Fluosol and carbogen. Cancer Res. 1987, 47:442-446.
200. 2 mapping. J. Biomed. Opt. 2003, 8:53-62.
201. Gu Y., Bourke V., Kim J.G., Constantinescu A., Mason R.P., Liu H. Dynamic response of breast tumor oxygenation to hyperoxic respiratory challenge monitored with three oxygen-sensitive parameters. Appl. Opt. 2003, 42:1-8.
202. Gallez B., Baudelet C., Jordan B.F. Assessment of tumor oxygenation by electron paramagnetic resonance: Principles and applications. NMR Biomed. 2004, 17:240-262.
203. Parhami P., Fung B.N. Fluorine-19 relaxation study of perfluorochemicals as oxygen carriers. J. Phys. Chem. 1983, 87:1928-1931.
204. Thomas S.R., Pratt R.G., Millard R.W., Samaratunga R.C., Shiferaw Y., Clark L.C., Hoffmann R.E. Evaluation of the influence of the aqueous phase bioconstituent environment on the F-19 T1 of perfluorocarbon blood substitute emulsions. J. Magn. Reson. Imag. 1994, 4:631-635.
205. 19F and proton relaxation rates of the perfluorochemical blood substitute FC-43 emulsion. J. Magn. Reson. 1984, 57:447-452.
206. 19F NMR imaging of blood oxygenation in the brain. Magn. Reson. Med. 1988, 6:344-352.
207. 19F spectroscopy of perfluorocarbon. Magn. Reson. Med. 1993, 29:296-302.
208. 2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field. Magn. Reson. Imaging 1996, 14:103-114.
209. 19F MRI: Molecule-specific imaging. Magn. Reson. Imaging 1990, 8:729-736.
210. 19F spin-echo images. Magn. Reson. Med. 1991, 17:178-188.
211. Sotak C.H., Hees P.S., Huang H.N., Hung M.H., Krespan C.G., Raynolds S. A new perfluorocarbon for use in fluorine-19 MRI and MRS. Magn. Reson. Med 1993, 29:188-195.
212. Zhao D., Ran S., Constantinescu A., Hahn E.W., Mason R.P. Tumor oxygen dynamics: Correlation of in vivo MRI with histological findings. Neoplasia 2003, 5:308-318.
213. Zhao D., Constantinescu A., Chang C.H., Hahn E.W., Mason R.P. Correlation of tumor oxygen dynamics with radiation response of the dunning prostate R3327-HI tumor. Radiat. Res. 2003, 159:621-631.
214. Zhao D., Constantinescu C., Hahn E.W., Mason R.P. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53:744-756.
215. Zhao D., Constantinescu A., Jiang L., Hahn E.W., Mason R.P. Prognostic radiology: Quantitative assessment of tumor oxygen dynamics by MRI. Am. J. Clin. Oncol. 2001, 24:462-466.
216. Zhao D., Constantinescu A., Hahn E.W., Mason R.P. Tumor oxygen dynamics with respect to growth and respiratory challenge: Investigation of the Dunning prostate R3327-HI tumor. Radiat. Res. 2001, 156:510-520.
217. Song Y., Constantinescu A., Mason R.P. Dynamic breast tumor oximetry: The development of prognostic radiology. Technol. Cancer Res. Treat. 2002, 1:471-478.
218. 19F inversion-recovery echo-planar imaging of Perfluoro-15-crown-5-ether. Magn. Reson. Med. 1994, 32:88-97.
219. Wang Z., Su M.Y., Nalcioglu O. Applications of dynamic contrast enhanced MRI in oncology: Measurement of tumor oxygen tension. Technol. Cancer Res. Treat. 2002, 1:29-38.
220. van der Sanden B.J.P., Heerschap A., Hoofd L., Simonetti A.W., Nicolay K., van der Toorn A., Colier W.N.M., van der Kogel A.J. Effect of carbogen breathing on the physiological profile of human glioma xenografts. Magn. Reson. Med. 1999, 42:490-499.
221. Duong T.Q., Iadecola C., Kim S.G. Effect of hyperoxia, hypercapnia, and hypoxia on cerebral interstitial oxygen tension and cerebral blood flow. Magn. Reson. Med. 2001, 45:61-70.
222. Girard F., Poulet P., Namer I.J., Steibel J., Chambron J. Localized T-2 measurements using an osiris-CPMG method-application to measurements of blood oxygenation and transverse relaxation free of diffusion effect. NMR Biomed. 1994, 7:343-348.
223. Mason R.P., Shukla H.P., Antich P.P. Oxygent: A novel probe of tissue oxygen tension. Biomater. Artif. Cells Immobilization. Biotechnol. 1992, 20:929-935.
224. 19F NMR indicator of tumor oxygenation. NMR Biomed. 1996, 9:125-134.
225. 2 and Temperature In Vivo with Rapid Time Resolution 1995, (Ed. US patent No.5, 397, 562).
226. Riess J.G. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomater. Artif. Cells Immobilization Biotech. 1992, 20:183-202.
227. Kaufman R.J., Goldstein J. Medical Oxygen Transport Using Perfluorochemicals 1991, 127-158. Butterworth-Heinemann, N.Y.
228. Zuck T.F., Riess J.G. Current status of injectable oxygen carriers. [Review]. Crit. Rev. Clin. Lab. Sci. 1994, 31:295-324.
229. Krafft M.P. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv. Drug Deliv. Rev. 2001, 47:209-228.
230. Schutt E.G., Klein D.H., Mattrey R.M., Riess J.G. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: The key role of perfluorochemicals. Angew. Chem. Int. Ed. 2003, 42:3218-3235.
231. Riess J.G. Oxygen carriers ("blood substitutes")-raison d'etre, chemistry, and some physiology. Chem. Rev. 2001, 101:2797-2920.
232. 19F NMR imaging of the vascular system in vivo. Magn. Reson. Imag. 1987, 5:279-285.
233. Fishman J.E., Joseph P.M., Carvlin M.J., Saadi-Elmandjra M., Mukherji B., Sloviter H.S. In vivo measurements of vascular oxygen tension in tumors using MRI of a fluorinated blood substitute. Invest. Radiol. 1989, 24:65-71.
234. 19F imaging of cerebral blood oxygenation in experimental middle cerebral artery occlusion: Preliminary results. J. Cereb. Blood Flow Metab. 1988, 8:276-281.
235. Noth U., Morrissey S.P., Deichmann R., Adolf H., Schwarzbauer C., Lutz J., Haase A. In vivo measurement of partial oxygen pressure in large vessels and in the reticuloendothelial system using fast 19F-MRI. Magn. Reson. Med. 1995, 34:738-745.
236. Hoard K.M. Measurement of Flow Rates Using Surface Coil Nuclear Magnetic Resonance 1989, University of Arlington, Arlington, Vol. MSc.
237. Higuchi T., Naruse S., Horikawa Y., Hirakawa K., Tanaka C. In vivo measurement of the partial pressure of oxygen in brain tissue using 19F NMR 1988, 435.
238. 19F MRI study in tumor-bearing mice. Magn. Reson. Imag. 1989, 7:475-485.
239. Mattrey R.F., Long D.C. Potential role of PFOB in diagnostic imaging. Invest. Radiol. 1988, 23:s298-s301.
240. Rosenblum W.I., Hadfield M.G., Martinez A.J., Schatzki P. Alterations of liver and spleen following intravenous infusion of fluorocarbon emulsions. Arch. Pathol. Lab. Med. 1976, 100:213-217.
241. 19F NMR probe at 4.7 T. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:1361-1367.
242. Mason R.P., Antich P.P., Babcock E.E., Constantinescu A., Peschke P., Hahn E.W. Non-invasive determination of tumor oxygen tension and local variation with growth. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29:95-103.
243. 19F NMR spectroscopy of sequestered perfluorocarbon emulsion. Magn. Reson. Med. 1992, 27:310-317.
244. 19F surface coil spectroscopy of sequestered perfluorocarbon emulsion. Magn. Reson. Med. 1991, 18:71-79.
245. 31P magnetic resonance spectroscopy. Magn. Reson. Imaging 1996, 14:541-551.
246. 19F MRI of sequestered perfluorocarbon. Magn. Reson. Med. 1996, 35:827-833.
247. 19F-MR relaxometry. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44:649-658.
248. 2in vivo using perflubron. Acad. Radiol. 1995, 2:756-761.
249. Helmer K.G., Han S., Sotak C.H. On the correlation between the water diffusion coefficient and oxygen tension in RIF-1 tumors. NMR Biomed. 1998, 11:120-130.
250. 19F echo planar NMR imaging of sequestered perfluorocarbon. J. Magn. Reson. Imaging 1994, 4:595-602.
251. Fan X., River J.N., Zamora M., Al-Hallaq H.A., Karczmar G.S. Effect of carbogen on tumor oxygenation: Combined fluorine-19 and proton MRI measurements. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:1202-1209.
252. 19F NMR. Magn. Reson. Med. 1993, 29:446-458.
253. 19F NMR relaxometry of a perfluorocarbon emulsion. Magn. Reson. Med. 1993, 29:303-310. and erratum 329 716 (1993).
254. 19F MRI of perfluorocarbons. Curr. Sci. 1999, 76:753-762.
255. Antich P.P., Mason R.P., Constantinescu A., Peschke P., Hahn E.W. MRI staining: A novel approach to tumor architecture using perfluorocarbons. Proc. Soc. Nucl. Med. 1994, 35(5):216P.
256. Berkowitz B.A., Wilson C.A., Hatchell D.L. Oxygen kinetics in the vitreous substitute perfluorotributylamine: A 19F NMR study in vivo. Invest. Ophthalmol. Vis. Sci. 1991, 32:2382-2387.
257. Wilson C.A., Berkowitz B.A., Hatchell D.L. Oxygen kinetics in preretinal perfluorotributylamine. Exp. Eye Res. 1992, 55:119-126.
258. Zhang W., Ito Y., Berlin E., Roberts R., Berkowitz B.A. Role of hypoxia during normal retinal vessel development and in experimental retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2003, 44:3119-3123.
259. Delpuech J.J., Hamza M.A., Serratice G., Stébé M.J. Fluorocarbons as oxygen carriers. I. An NMR study of oxygen solutions in hexafluorobenzene. J. Chem. Phys. 1979, 70:2680-2687.
260. Hamza M.A., Serratice G., Stebe M.J., Delpuech J.J. Solute-solvent interactions in perfluorocarbon solutions of oxygen. An NMR study. J. Am. Chem. Soc. 1981, 103:3733-3738.
261. Rietjens I.M.C.M., Steensma A., den Besten C., van Tintelen G., Haas J., van Ommen B., van Bladeren P.J. Comparative biotransformation of hexachlorobenzene and hexafluorobenzene in relation to the induction of porphyria. Eur. J. Pharmacol. 1995, 293:292-299.
262. Gorsman Y.S., Kapitonenko T.A. Pharmacology and toxicology of hexafluorobenzene. Izv. Estestvennonauchu. Inst. Pevinsk. 1973, 15:155-163.
263. Mortelmans K.M., Simmon V.F. "In vitro" microbiological mutagenicity assays of eight fluorocarbon taggant samples. Gov. Rep. Announce. Index. (US). 1981, 81:2555-2587.
264. Courtney K.D., Andrews J.E. Teratogenic evaluation and fetal deposition of hexabromobenzene (HBB) and hexafluorobenzene (HFB) in CD-1 mice. J. Environ. Sci. Health B 1984, 19:83-94.
265. Hall L.W., Jackson S.R.K., Massey G.M., Arias A. Hexafluorobenzene in veterinary anaesthesia 1975, 201-204. Excerpta Medica, Oxford. R. Llaurado, M.A. Nalda, J.N. Lunn (Eds.).
266. 19F NMR spectroscopy of hexafluorobenzene. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40:161-171.
267. Zhao D., Jiang L., Hahn E.W., Mason R.P. Tumor physiological response to combretastatin A4 phosphate assessed by MRI. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:872-880.
268. 19F PBSR EPI of hexafluorobenzene. Magn. Reson. Imaging, 1997, 15:971-981.
269. Hunjan S., Zhao D., Constantinescu A., Hahn E.W., Antich P.P., Mason R.P. Tumor oximetry: Demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:1097-1108.
270. 19F magnetic resonance imaging in rats. Phys. Med. Biol. 2006, 51:45-60.
271. 19F MR EPI and electrodes 2003, Vol. 530:19-28. Kluwer, New York. J.F. Dunn, H.M. Swartz (Eds.).
272. Mason R.P., Constantinescu A., Hunjan S., Le D., Hahn E.W., Antich P.P., Blum C., Peschke P. Regional tumor oxygenation and measurement of dynamic changes. Radiat. Res. 1999, 152:239-249.
273. Bourke V., Gilio J., Zhao D., Constantinescu A., Kodibagkar V., Jiang L., Hahn E.W., Mason R.P. Correlation of radiation response with tumor oxygenation in the Dunning prostate R3327-AT1 Tumor. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:1179-1186.
274. Rofstad E.K., Sundfor K., Lyng H., Trope C.G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 2000, 83:354-359.
275. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintile M., Sun A., Chapman W., Levin W., Manchul L., Keane T.J., Hill R.P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 1998, 48:149-156.
276. Höckel M., Schlenger K., Aral B., Mitze M., Schäffer U., Vaupel P. Hypoxia and radiation response in human tumors. Semi. Radiat. Oncol. 1996, 6:3-9.
277. Keupp J., Schaeffter T. Proc. Intl. Soc. Mag. Reson. Med. 2006, 916. (Seattle).
278. Griffiths J.R. Are cancer cells acidic?. Br. J. Cancer 1991, 64:425-427.
279. 19F NMR spectroscopy. FEBS Lett. 1994, 349:234-238.
280. 19F NMR. Ann. N. Y. Acad. Sci. 1987, 508:33-47.
281. 19F NMR. Proc. Natl. Acad. Sci. USA 1982, 79:7944-7948.
282. Deutsch C., Taylor J.S., Price M. pH homeostasis in human lymphocytes: Modulation by ions and mitogen. J. Cell Biol. 1984, 98:885-894.
283. Kashiwagura T., Deutsch C.J., Taylor J., Erecinska M., Wilson D.F. Dependence of gluconeogenesis, urea synthesis, and energy metabolism of hepatocytes on intracellular pH. J. Biol. Chem. 1984, 259:237-243.
284. 31P NMR. NMR Biomed. 1988, 1:95-100.
285. 19F NMR indicators of intracellular pH. Biophys. J. 1983, 43:261-267.
286. Joseph A., Davenport C., Kwock L., Burt C.T., London R.E. Fluorine-19 NMR studies of tumor-bearing rats treated with difluoromethylornithine. Magn. Reson. Med. 1987, 4:137-143.
287. 19F NMR using trifluoroacetate and trifluoroacetamide probes. Biochemistry 1989, 28:2378-2382.
288. Xu A.S.L., Potts J.R., Kuchel P.W. The phenomenon of separate intracellular and extracellular resonances of difluorophosphate in P-31 and F-19 Nmr-spectra of erythrocytes. Magn. Reson. Med. 1991, 18:193-198.
289. Xu A.S.L., Waldeck A.R., Kuchel P.W. Transmembrane F-19 Nmr chemical-shift difference of fluorinated solutes in liposomes, erythrocytes and erythrocyte-ghosts. NMR Biomed. 1993, 6:136-143.
290. 19F NMR of 6-Fluoropyridoxol. Magn. Reson. Med. 1998, 39:551-556.
291. 6 analogs. Bioorg. Med. Chem. 1998, 6:1631-1639.
292. 6 group. J. Am. Chem. Soc. 1963, 85:2813-2817.
293. Yamada K., Tsuji M. Transport of vitamin B6 in human erythrocytes. J. Vitaminol. 1970, 16:237-242.
294. Yu J.X., Otten P., Ma Z., Cui W., Liu L., Mason R.P. A novel NMR platform for detecting gene transfection: Synthesis and evaluation of fluorinated phenyl β-d-Galactosides with potential application for assessing LacZ gene expression. Bioconjug. Chem. 2004, 15:1334-1341.
295. 19F NMR. Cell Calcium 1985, 6:183-195.
296. 19F NMR indicators of hepatic intra cellular pH in vivo. Biochem. Soc. Trans. 1987, 15:871-872.
297. 19F pH indicators: Fluoroanilines. Biophys. J. 1989, 55:799-804.
298. Rhee C.K., Levy L.A., London R.E. Fluorinated o-aminophenol derivatives for measurement of intracellular pH. Bioconjug. Chem. 1995, 6:77-81.
299. 19F NMR of trifluoromethylated Aryl β-d-galactopyranosides. Bioorg. Med. Chem. 2006, 14:326-333.
300. Cui W., Otten P., Yu J., Kodibagkar V., Mason R.P. 6-trifluoromethyl pyridoxol, a novel reporter molecule for tumor extracellular pH. Proc. ISMRM (Toronto, Canada) 2003, 675.
301. Frenzel T., Koszler S., Bauer H., Niedballa U., Weinmann H.J. Noninvasive in vivo pH measurement using a fluorinated pH probe and fluorine-19 magnetic resonance spectroscopy. Invest. Radiol. 1994, 29:S220-S222.
302. 19F MRS, to in vivo pH measurement after hyperthermic treatment of tumors in mice. Acad. Radiol. 1996, 3:S363-S364.
303. Ojugo A.S., McSheehy P.M., McIntyre D.J., McCoy C., Stubbs M., Leach M.O., Judson I.R., Griffiths J.R. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: A comparison of exogenous (19)F and (31)P probes. NMR Biomed. 1999, 12:495-504.
304. 19F MR spectroscopy. Invest. Radiol. 1996, 31:680-689.
305. Tsien R.Y. A non-disruptive technique for loading calcium buffers and indicators into cells. Nature 1981, 290:527-528.
306. Smith G.A., Hesketh R.T., Metcalfe J.C., Feeney J., Morris P.G. Intracellular calcium measurements by F-19 Nmr of fluorine-labeled chelators. Proc. Natl. Acad. Sci. USA 1983, 80:7178-7182.
307. Benters J., Flogel U., Schafer T., Leibfritz D., Hechtenberg S., Beyersmann D. Study of the interactions of cadmium and zinc ions with cellular calcium homoeostasis using F-19-NMR spectroscopy. Biochem. J. 1997, 322:793-799.
308. 19F NMR Measurement of Intracellular Free Calcium Ions In Intact Cells and Tissues 1987, Vol. 2:45-53. CRC, Boca Raton. R.K. Gupta (Ed.).
309. Schanne F.A., Moskal J.R., Gupta R.K. Effect of lead on intracellular free calcium ion concentration in a presynaptic neuronal model: 19F-NMR study of NG108-15 cells. Brain Res. 1989, 503:308-311.
310. 19F NMR. Proc. Natl. Acad. Sci. USA 1989, 86:5133-5135.
311. Marban E., Kitakaze M., Chacko V.P., Pike M.M. Ca-2+ transients in perfused hearts revealed by gated F-19 NMR-spectroscopy. Circ. Res. 1988, 63:673-678.
312. 2+ and pH in shaping myocardial contractile response to acute respiratory alkalosis. Am. J. Physiol. 1993, 265:H1696-H1703.
313. Kirschenlohr H.L., Metcalfe J.C., Morris P.G., Rodrigo G.C., Smith G.A. Ca-2+ Transient, Mg-2+, and pH Measurements in the cardiac cycle by F-19 NMR. Proc. Natl. Acad. Sci. USA 1988, 85:9017-9021.
314. Plenio H., Diodone R. Covalently bonded fluorine as a σ-donor for groups I and I metal ions in partially fluorinated macrocycles. JACS 1996, 118:356-367.
315. Noronha J.L., Matuschak G.M. Magnesium in critical illness: Metabolism, assessment, and treatment. Intensive Care Med. 2002, 28:667-679.
316. 31P NMR Measurement of Intracellular Free Magnesium in Cells and Organisms 1987, Vol. 2:34-43. CRC, Boca Raton. R.K. Gupta (Ed.).
317. Weller E., Bachert P., Meinck H.M., Friedmann B., Bartsch P., Mairbaurl H. Lack of effect of oral Mg-supplementation on Mg in serum, blood cells, and calf muscle. Med. Sci. Sports Exerc. 1998, 30:1584-1591.
318. Odvina C.V., Mason R.P., Pak C.Y.C. Prevention of thiazide-induced hypokalemia without magnesium depletion by potassium-magnesium citrate. Am. J. Ther. 2006, 13:101-108.
319. Murphy E. Measurement of intracellular ionized magnesium. Miner. Electrolyte Metab. 1993, 19:250-258.
320. 13C NMR. Chem. Res. Toxicol. 1989, 2:429-435.
321. 19F NMR. Biochemistry 1988, 27:4041-4048.
322. Murphy E., Steenbergen C., Levy L.A., Raju B., London R.E. Cytosolic free magnesium levels in ischemic rat-heart. J. Biol. Chem. 1989, 264:5622-5627.
323. Long G.J., Rosen J.F., Schanne F.A.X. Lead activation of protein-kinase-C from rat-brain - determination of free calcium, lead, and zinc by F-19-Nmr. J. Biol. Chem. 1994, 269:834-837.
324. Plenio H., Hermann J., Diodone R. The coordination chemistry of fluorocarbons: Difluoro-m-cyclophane-based fluorocryptands and their group I and II metal ion complexes. Inorg. Chem. 1997, 36:5722-5729.
325. Takemura H., Kariyazono H., Yasutake M., Kon N., Tani K., Sako K., Shinmyozu T., Inazu T. Syntheses of macrocyclic compounds possessing fluorine atoms in their cavities: Structures and complexation with cations. Eur. J. Org. Chem. 2000, 1:141-148.
326. Plenio H., Diodone R. A fluorine-containing cryptand for the complexation of anions and the utility of F-19 Nmr-spectroscopy for the determination of host guest association. Z. Naturforsch. Section. B-. J. Chem. Sci. 1995, 50:1075-1078.
327. London R.E., Gabel S.A. F-19 NMR-studies of fluorobenzeneboronic acids.1. Interaction kinetics with biologically significant. JACS 1994, 116:2562-2569.
328. Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S. 2-deoxy-2-[18F]fluoro-D-glucose and alternative radiotracers for positron emission tomography imaging using the human brain as a model. Semin. Nucl. Med. 2004, 34:112-121.
329. Nakada T., Kwee I.L., Conboy C.B. Noninvasive in vivo denonstration of 2-fluoro-2-deoxy-d-glucose metabolism beyond the hexokinase reaction in rat-brain by F-19 nuclear-magnetic-resonance spectroscopy. J. Neurochem. 1986, 46:198.
330. Nakada T., Kwee I.L., Card P.J., Matwiyoff N.A., Griffey B.V., Griffey R.H. F-19 NMR imaging of glucose-metabolism. Magn. Reson. Med. 1988, 6:307-313.
331. Nakada T., Kwee I.L., Griffey B.V., Griffey R.H. F-19 Mr imaging of glucose-metabolism in the rabbit. Radiology 1988, 168:823-825.
332. Berkowitz B.A., Ackerman J.J.H. Proton decoupled fluorine nuclear-magnetic-resonance spectroscopy in situ. Biophys. J. 1987, 51:681-685.
333. Lizak M.J., Mori K., Kador P.F. Determination of aldose reductase activity in the eye by localized magnetic resonance spectroscopy. J. Ocul. Pharmacol. Ther. 2001, 17:475-483.
334. Secchi E.F., Lizak M.J., Sato S., Kador P.F. 3-Fluoro-3-deoxy-d-galactose: A new probe for studies on sugar cataract. Curr. Eye Res. 1999, 18:277-282.
335. Kwee I.L., Igarashi H., Nakada T. Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: In vivo kinetic studies using F-19 3-FDG NMR in rats. Neuroreport 1996, 7:726-728.
336. Shulman R.G., Rothman D.L. C-13 NMR of intermediary metabolism: Implications for systemic physiology. Annu. Rev. Physiol. 2001, 63:15-48.
337. Jeffrey F.M.H., Rajagopal A., Malloy C.R., Sherry A.D. C-13-Nmr - a simple yet comprehensive method for analysis of intermediary metabolism. Trends Biochem. Sci. 1991, 16:5-10.
338. Mason R.P., Sanders J.K.M., Cornish A. In vivo enzymology-C-13 Nmr measurement of a kinetic isotope effect for methanol oxidation in methylosinus-trichosporium Ob3b. FEBS Lett. 1987, 216:4-6.
339. Stratford I.J., Adams G.E., Steel G.G. Radiation Sensitizers and Bioreductive Drugs 1989, 145-162. Elsevier, Amsterdam. G.E. Adams, A. Horwich (Eds.).
340. Foo S.S., Abbott D.F., Lawrentschuk N., Scott A.M. Functional imaging of intratumoral hypoxia. Mol. Imaging. Biol. 2004, 6:291-305.
341. Franko A., Koch C., Boisvert D. Distribution of misonidazole adducts in gliosarcoma tumors and spheroids: Implications for oxygen distribution. Cancer Res. 1992, 52:3831-3837.
342. Ballinger J.R. Imaging hypoxia in tumors. Semin. Nucl. Med. 2001, 31:321-329.
343. Hodgkiss R.J. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des. 1998, 13:687-702.
344. Rajendran J.G., Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. North Am. 2005, 43:169-187.
345. Evans S.M., Hahn S., Pook D.R., Jenkins W.T., Chalian A.A., Zhang P., Stevens C., Weber R., Weinstein G., Benjamin I., Mirza N., Morgan M., Rubin S., McKenna W.G., Lord E.M., Koch C.J. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000, 60:2018-2024.
346. Koch C.J., Hahn S.M., Rockwell K.J., Covey J.M., McKenna W.G., Evans S.M. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: Implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother. Pharmacol. 2001, 48:177-187.
347. Ljungkvist A.S.E., Bussink J., Rijken P.F.J.W., Raleigh J.A., Denekamp J., Van Der Kogel A.J. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:1529-1538.
348. Lewis J.S., McCarthy D.W., McCarthy T.J., Fujibayashi Y., Welch M.J. Evaluation of Cu-64-ATSM in vitro and in vivo in a hypoxic tumor model. J. Nucl. Med. 1999, 40:177-183.
349. Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., Welch M.J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55:1233-1238.
350. Chapman J.D., Engelhardt E.L., Stobbe C.C., Schneider R.F., Hanks G.E. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol. 1998, 46:229-237.
351. 19F nuclear magnetic resonance methodologies for the asssessment of tumour hypoxia. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2004, 359:987-996.
352. 19F 2D-CSI investigation of a fluorine labeled 2-Nitroimidazole (TF-MISO). A potential functional reporter of hypoxia in solid tumors. Proc. Intl. Soc. Mag. Reson. Med. 2006, 1260.
353. Cline J.M., Rosner G.L., Raleigh J.A., Thrall D.E. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37:655-662.
354. Workman P., Maxwell R.J., Griffiths J.R. Noninvasive MRS in New Anticancer Drug Development. NMR Biomed. 1992, 5:270-272.
355. Seddon B.M., Maxwell R.J., Honess D.J., Grimshaw R., Raynaud F., Tozer G.M., Workman P. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin. Cancer Res. 2002, 8:2323-2335.
356. Seddon B.M., Payne G.S., Simmons L., Ruddle R., Grimshaw R., Tan S., Turner A., Raynaud F., Halbert G., Leach M.O., Judson I., Workman P. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin. Cancer Res. 2003, 9:5101-5112.
357. Li S.J., Jin G.Y., Moulder J.E. Prediction of tumor radiosensitivity by hexafluoromisonidazole retention monitored by [H-1]/[F-19] magnetic-resonance spectroscopy. Cancer Commun. 1991, 3:133-139.
358. Aboagye E.O., Maxwell R.J., Horsman M.R., Lewis A.D., Workman P., Tracy M., Griffiths J.R. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br. J. Cancer 1998, 77:65-70.
359. 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother. Oncol. 2004, 73:359-366.
360. Fairweather J.K., Faijes M., Driguez H., Planas A. Specificity studies of bacillus 1,3-1,4-beta-glucanases and application to glycosynthase-catalyzed transglycosylation. Chembiochem 2002, 3:866-873.
361. Ichikawa T., Hogemann D., Saeki Y., Tyminski E., Terada K., Weissleder R., Chiocca E.A., Basilion J.P. MRI of transgene expression: Correlation to therapeutic gene expression. Neoplasia (New York) 2002, 6:523-530.
362. Paroo Z., Bollinger R.A., Braasch D.A., Richer E., Corey D.R., Antich P.P., Mason R.P. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol. Imaging 2004, 3:117-124.
363. Tjuvajev J.G., Doubrovin M., Akhurst T., Cai S., Balatoni J., Alauddin M.M., Finn R., Bornmann W., Thaler H., Conti P.S., Blasberg R.G. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J. Nucl. Med. 2002, 43:1072-1083.
364. Kruger A., Schirrmacher V., Khokha R. The bacterial lacZ gene: An important tool for metastasis research and evaluation if new cancer therapies. Cancer Metastasis Rev. 1999, 17:285-294.
365. Serebriiskii I.G., Golemis E.A. Uses of lacZ to study gene function: Evaluation of beta-galactosidase assays employed in the yeast two-hybrid system. Anal. Biochem. 2000, 285:1-15.
366. Beckwith J.R., Zipser D. The Lactose Operon 1970, 435. Cold Spring Harbor Laboratory, Cold Spring Harbor.
367. Kawaguchi J., Wilson V., Mee P.J. Visualization of whole-mount skeletal expression patterns of LacZ reporters using a tissue clearing protocol. Biotechniques 2002, 32:68-73.
368. Heuermann K., Cosgrove J. S-Gal: An autoclavable dye for color selection of cloned DNA inserts. Biotechniques 2001, 30:1142-1147.
369. Bronstein I., Edwards B., Voyta J.C. 1,2-Dioxetanes-novel chemi-luminescent enzyme substrates-applications to immunoassays. J. Chemilum. Biolum. 1989, 4:99-111.
370. Louie A.Y., Huber M.M., Ahrens E.T., Rothbacher U., Moats R., Jacobs R.E., Fraser S.E., Meade T.J. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 2000, 18:321-325.
371. Tung C.H., Zeng Q., Shah K., Kim D.E., Schellingerhout D., Weissleder R. In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res. 2004, 64:1579-1583.
372. Lee K.H., Byun S.S., Choi J.H., Paik J.Y., Choe Y.S., Kim B.T. Targeting of lacZ reporter gene expression with radioiodine-labelled phenylethyl-beta-d-thiogalactopyranoside. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:433-438.
373. Yoon S., Kim H.G., Chun K.H., Shin J.E.N. 4-deoxy-analogs of p-nitrophenyl β-d-galactopyranosides for specificity study with β-galactosidase from escherichia coli. Bull. Korean Chem. Soc. 1996, 17:599-604.
374. Cui W., Otten P., Li Y., Koeneman K., Yu J., Mason R.P. A novel NMR approach to assessing gene transfection: 4-fluoro-2-nitrophenylβ-d-galactopyranoside as a prototype reporter molecule for β-galactosidase. Magn. Reson. Med. 2004, 51:616-620.
375. 19F chemical shift imaging of LacZ gene-reporter molecule 2-fluoro-4-nitrophenolβ-d-galactopyranoside. Magn. Reson. Imaging 2006, 24:959-962.
376. Richard J.P., Westerfeld J.G., Lin S. Structure-reactivity relationships for beta-galactosidase (Escherichia coli, lac Z). 1. Bronsted parameters for cleavage of alkyl beta-d-galactopyranosides. Biochemistry 1995, 34:11703-11712.
377. 19F NMR of a fluorinated vitamin B6 conjugate. Med. Chem. 2005, 1:255-262.
378. 19F NMR of polyglycosylated fluorinated vitamin B6. J. Med. Chem. 2006, 49:1991-1999.
379. 19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl β-d-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse. Faseb J. 2007, 21:2014-2019.
380. Clark L.C., Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966, 152:1755-1756.
381. Greenspan J.S., Fox W.W., Rubenstein S.D., Wolfson M.R., Spinner S.S., Shaffer T.H. Partial liquid ventilation in critically ill infants receiving extracorporeal life support. Philadelphia Liquid Ventilation Consortium. Pediatrics 1997, 99:E2.
382. Thomas S.R., Clark L.C., Ackerman J., Pratt R.G., Hoffmann R.E., Busse L.J., Kinsey R.A., Samaratunga R.C. MRI imaging of the lung using liquid perfluorocarbons. J. Comput. Asst. Tomogr. 1986, 10:1-9.
383. 2. Invest. Radiol. 1997, 32:29-38.
384. Huang M.Q., Ye Q., Williams D.S., Ho C. MRI of lungs using partial liquid ventilation with water-in-perfluorocarbon emulsions. Magn. Reson. Med. 2002, 48:487-492.
385. E. Heidelberger, P.C. Lauterbur, 1982, pp. 70-71.
386. 6. Magn. Reson. Med. 2002, 48:547-549.
387. 6 composition on apparent diffusion coefficients. Resp. Physiol. Neurobiol. 2005, 148:43-56.
388. Remy W.F., Geenen R.W., Hussain S.M., Cademartiri F., Poley J.W., Siersema P.D., Krestin G.P. CT and MR colonography: Scanning techniques, postprocessing, and emphasis on polyp detection. Radiograph 2004, 24:e18.
389. Rubin D.L., Falk K.L., Sperling M.J., Ross M., Saini S., Rothman B., Shellock F., Zerhouni E., Stark D., Outwater E.K., Schmiedl U., Kirby L.C., Chezmar J., Coates T., Chang M., Silverman J.M., Rofsky N., Burnett K., Engel J., Young S.W. A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI. [Clinical Trial. Clinical Trial, Phase II. Clinical Trial, Phase III. J. Magn. Reson. Imaging 1997, 7:865-872.
390. Hirohashi S., Uchida H., Yoshikawa K., Fujita N., Ohtomo K., Yuasa Y., Kawamura Y., Matsui O. Large scale clinical evaluation of bowel contrast agent containing ferric ammonium citrate in MRI. Magn. Reson. Imaging 1994, 12:837-846.
391. Bisset G.S.I., Emery K.H., Meza M.P., Rollins N.K., Don S., Shorr J.S. Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population. Pediatr. Radiol. 1996, 26:409-415.
392. Mattrey R.F., Trambert M.A., Brown J.J., Young S.W., Bruneton J.N., Wesbey G.E., Balsara Z.N. Perflubron as an oral contrast agent for MR imaging: Results of a phase III clinical trial. Radiology 1994, 191:841-848.
393. Uzzan B., Nicolas P., Cucherat M., Perret G.Y. Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res. 2004, 64:2941-2955.
394. Robinson S.P., Rijken P.F., Howe F.A., McSheehy P.M., van der Sanden B.P., Heerschap A., Stubbs M., Van Der Kogel A.J., Griffiths J.R. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J. Magn. Reson. Imaging. 2003, 17:445-454.
395. Ceckler T.L., Gibson S.L., Hilf R., Bryant R.G. In situ assessment of tumor vascularity using fluorine NMR imaging. Magn. Reson. Med. 1990, 13:416-433.
396. Meyer K.L., Joseph P.M., Mukherji B., Livolsi V.A., Lin R. Measurement of vascular volume in experimental rat-tumors by F-19 magnetic-resonance-imaging. Invest. Radiol. 1993, 28:710-719.
397. Sogabe T., Imaizumi T., Mori T., Tominaga M., Koga K., Yabuuchi Y. Effects of vasodilators on the signal intensity of perfluorocarbon monitored by in vivo F-19-NMR spectroscopy. Magn. Reson. Imaging 1997, 15:341-345.
398. 19F magnetic resonance spectroscopy. Opt. Express. 2005, 13:1724-1733.
399. Authier B. Reactive hyperemia monitored on rat muscle using perfluorocarbons and F-19 NMR. Magn. Reson. Med. 1988, 8:80-83.
400. 125I]-albumin and correlation to tumor size. Magn. Reson. Imaging 1996, 14:275-280.
401. Ewing J.R., Branch C.A., Fagan S.C., Helpern J.A., Simkins R.T., Butt S.M., Welch K.M.A. Fluorocarbon-23 measure of cat cerebral blood flow by NMR. Stroke 1990, 21:100-106.
402. Eleff S.M., Schnall M.D., Ligetti L., Osbakken M., Subramanian V.H., Chance B., Leigh J.S. concurrent measurements of cerebral blood-flow, sodium, lactate, and high-energy phosphate-metabolism using F-19, Na-23, H-1, and P-31 nuclear magnetic-resonance spectroscopy. Magn. Reson. Med. 1988, 7:412-424.
403. Van den Brink J.S., Watanabe Y., Kuhl C.K., Chung T., Muthupillai R., Van Cauteren M., Yamada K., Dymarkowski S., Bogaert J., Maki J.H., Matos C., Casselman J.W., Hoogeveen R.M. Implications of SENSE MR in routine clinical practice. Eur. J. Radiol. 2003, 46:3-27.
404. Pruessmann K.P., Weiger M., Scheidegger M.B., Boesiger P. SENSE: Sensitivity encoding for fast MRI. Magn. Reson. Med. 1999, 42:952-962.
405. Shukla H.P. Application of Perfluorocarbon Emulsions as Fluorine-19 Nuclear Magnetic Resonance Molecular Probes of Cardiac Tissue Oxygen Tension 1994, University of Texas Southwestern Graduate School of Biomedical Sciences, Ph.D.
406. 2] and pH in biological systems. Biophys. J. 1988, 53:227-233.
407. 2 by spin-spin relaxation rate 1/T2 of 19F in a rabbit abscess model. Artif Cells Blood Substit. Immobil. Biotechnol. 1994, 22:1449-1454.
408. Delpuech J.J., Hamza M.A., Serratrice G. Determination of oxygen by a nuclear magnetic-resonance method. J. Magn. Reson. 1979, 36:173-179.
409. Raghunand N., Gillies R.J. pH and chemotherapy. Novartis Foundation Symposium 2001, 240:199-211.
410. 19F-NMR. Biochim. Biophys. Acta 1986, 889:72-83.
411. Ramasamy R., Zhao P., Gitomer W.L., Sherry A.D., Malloy C.R. Determination of chloride potential in perfused rat hearts by NMR spectroscopy. Am. J. Physiol. 1993, 263:H1958-H1962.
412. Bobko A.A., Sergeeva S.V., Bagryanskaya E.G., Markel A.L., Khramtsov V.V., Reznikov V.A., Kolosova N.G. 19F NMR measurements of NO production in hypertensive ISIAH and OXYS rats. Biochem. Biophys. Res. Commun. 2005, 330:367-370.
413. Raleigh J., Franko A., Kelly D., Trimble L., Allen P. Development of an in vivo 19F MR method for measuring oxygen deficiency in tumors. Magn. Reson. Med 1991, 22:451-466.
414. Daugherty A., Becker N.N., Scherrer L.A., Sobel B.E., Ackerman J.J.H., Baynes J.W., Thorpe S.R. Non-invasive detection of protein-metabolism In vivo by NMR-spectroscopy-Application of a novel F-19-containing residualizing label. Biochem. J. 1989, 264:829-835.
415. 19F NMR. NMR Biomed. 1992, 5:65-68.
416. Duong T.Q., Ackerman J.J.H., Ying H.S., Neil J.J. Evaluation of extra- and intracellular apparent diffusion in normal and globally ischemic rat brain via F-19 NMR. Magn. Reson. Med. 1998, 40:1-13.
417. Thomas C., Counsell C., Wood P., Adams G.E. Use of F-19 nuclear-magnetic-resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice. J. Natl. Cancer Inst. 1992, 84:174-180.
418. Nunnally R.L., Babcock E.E., Horner S.D., Peshock R.M. Fluorine-19 NMR spectroscopy and imaging investigations of myocardial perfusion and cardiac function. Magn. Reson. Imaging 1985, 3:399-405.
419. Tibes R., Trent J., Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Ann. Rev. Pharmacol. Toxicol. 2005, 45:357.
420. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa(R)) Tablets. Oncologist 2003, 8:303-306.
421. Neri R. Pharmacology and pharmacokinetics of flutamide. Urology 1989, 34:19-21.
422. Eliason R., Schoenau J.J., Szmigielski A.M., Laverty W.M. Phytotoxicity and persistence of flucarbazone-sodium in soil. Weed Sci. 2004, 52:857-862.
423. Moon J.K., Kim J.H., Rhee S., Kim G., Yun H., Chung B.J., Lee S., Lim Y. Structural investigation of bistrifluron using X-ray crystallography, NMR spectroscopy, and molecular modeling. Bull. Korean Chem. Soc. 2002, 23:1545-1547.
424. Christie P. Roflumilast: A selective phosphodiesterase 4 inhibitor. Drugs Today 2005, 41:667-675.
425. Haagsma K.A., Rust M.K. Effect of hexaflumuron on mortality of the Western subterranean termite (Isoptera: Rhinotermitidae) during and following exposure and movement of hexaflumuron in termite groups. Pest. Manag. Sci. 2005, 61:517-531.
426. Howell A. Fulvestrant ('Faslodex'): Current and future role in breast cancer management. Crit. Rev. Oncol. Hematol. 2006, 57:265-273.
427. Santora K.A., Zakson-Aiken M., Rasa C., Shoop W. Development of a mouse model to determine the systemic activity of potential flea-control compounds. Vet. Parasitol. 2002, 104:257-264.
428. Van Den Neste E., Cardoen S., Offner F., Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: Fludarabine and cladribine (Review). Int. J. Oncol. 2005, 27:1113-1124.
429. Blasco C., Font G., Manes J., Pico Y. Solid-phase microextraction liquid chromatography/tandem mass spectrometry to determine postharvest fungicides in fruits. Anal. Chem. 2003, 75:3606-3615.
430. Abu-Qare A.W., Abou-Donia M.B. Sarin: Health effects, metabolism, and methods of analysis. Food Chem. Toxicol. 2002, 40:1327-1333.
431. London R.E., Gabel S.A. F-19 NMR-studies of fluorobenzeneboronic acids.1. Interaction kinetics with biologically significant ligands. J. Am. Chem. Soc. 1994, 116:2562-2569.
432. 2 measurements. Biomater. Artif. Cells Immobization Biotechnol. 1992, 20:917-920.
433. Laukemper-Ostendorf S., Scholz A., Burger K., Heussel C.P., Schmittner M., Weiler N., Markstaller K., Eberle B., Kauczor H.U., Quintel M., Thelen M., Schreiber W.G. 19F-MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation. Magn. Reson. Med. 2002, 47:82-89.
434. Sotak C.H., Hees P.S., Huang H.H., Hung M.H., Krespan C.G., Reynolds S. A new perfluorocarbon for use in fluorine-19 magnetic resonance spectroscopy. Magn. Reson. Med. 1993, 29:188-195.
435. Papadopoulou M.V., Pouremad R., Rao M.K., Ji M., Bloomer W.D. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by F-19-magnetic resonance spectroscopy (F-19-MRS). In Vivo 2001, 15:365-371.